Top 15 women in pharma; Pay-for-delay deals face another setback;

> Who are the top 15 women in pharma? Our sister publication FiercePharma has unveiled their picks, and there's quite a few interesting names in the bunch. List

> Congress is one step closer to enacting a ban on deals paying generic drug makers to hold off on launching products competing with the big brands. A Senate panel voted yesterday to ban branded drugmakers from engaging in this practice, known as "pay for delay." FiercePharma

> Famed investor George Soros has taken a 7.1 percent stage in revenue cycle management vendor Emdeon. With the need for that industry climbing, seems he could have done worse. FierceHealthFinance

> By making some tweaks to how it used its core business intelligence system, Mount Sinai Medical Center managed to reclaim $3 million in missed charges within one year. Pretty cool, huh?  FierceHealthFinance

And Finally... If you're a customer at a bordello, one would think the only green they'd care about is the color of your money...but not here. Article